290 related articles for article (PubMed ID: 7449384)
1. Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate.
Kremer J; de Bruijn HW; Hindriks FR
Contraception; 1980 Oct; 22(4):359-67. PubMed ID: 7449384
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of the effects of subdermal levonorgestrel implant system and long acting progestogen injection method on lipid metabolism.
Anwar M; Soejono SK; Maruo T; Abdullah N
Asia Oceania J Obstet Gynaecol; 1994 Mar; 20(1):53-8. PubMed ID: 8172528
[TBL] [Abstract][Full Text] [Related]
3. [Injectable contraceptive, DMPA, serum HDL cholesterol and heart infarct].
Kremer J; de Bruijn HW; Hindriks FR
Ned Tijdschr Geneeskd; 1981 Aug; 125(35):1418-21. PubMed ID: 6456421
[TBL] [Abstract][Full Text] [Related]
4. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.
Garza-Flores J; De la Cruz DL; Valles de Bourges V; Sanchez-Nuncio R; Martinez M; Fuziwara JL; Pérez-Palacios G
Contraception; 1991 Jul; 44(1):61-71. PubMed ID: 1832626
[TBL] [Abstract][Full Text] [Related]
6. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women.
Fahmy K; Khairy M; Allam G; Gobran F; Alloush M
Contraception; 1991 Oct; 44(4):431-44. PubMed ID: 1836755
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.
Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K
Contraception; 1997 Jul; 56(1):1-3. PubMed ID: 9306024
[TBL] [Abstract][Full Text] [Related]
8. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
9. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
Pardthaisong T; Gray RH; McDaniel EB
Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
11. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
Potter LS; Dalberth BT; Cañamar R; Betz M
Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
[TBL] [Abstract][Full Text] [Related]
12. Bone density in long term users of depot medroxyprogesterone acetate.
Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
[TBL] [Abstract][Full Text] [Related]
13. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women.
Naessen T; Olsson SE; Gudmundson J
Contraception; 1995 Jul; 52(1):35-9. PubMed ID: 8521712
[TBL] [Abstract][Full Text] [Related]
14. Trabecular bone in long-term depot-medroxyprogesterone acetate users.
Virutamasen P; Wangsuphachart S; Reinprayoon D; Kriengsinyot R; Leepipatpaiboon S; Gua C
Asia Oceania J Obstet Gynaecol; 1994 Sep; 20(3):269-74. PubMed ID: 7811192
[TBL] [Abstract][Full Text] [Related]
15. Serum immunoglobulin levels during contraceptive use of depot-medroxyprogesterone acetate in Indian women: a preliminary study.
Lali P; Chandra L; Gupta RP
Contraception; 1996 Jun; 53(6):363-5. PubMed ID: 8773424
[TBL] [Abstract][Full Text] [Related]
16. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
17. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Oyelola OO
Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
[TBL] [Abstract][Full Text] [Related]
18. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.
Paiva LC; Pinto-Neto AM; Faundes A
Contraception; 1998 Dec; 58(6):351-5. PubMed ID: 10095971
[TBL] [Abstract][Full Text] [Related]
19. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
[TBL] [Abstract][Full Text] [Related]
20. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I; Khan AR; Jahan FA
Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
